CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

BioCardia to Support Development of Potential Cell Therapy Products

Life Sciences Review Life Sciences Review | Thursday, December 30, 2021
Tweet

The facility is being expanded to support the manufacturing of CardiAMP Cell Therapy Systems, allogeneic NK1R+ MSC, and biotherapeutic delivery devices for clinical trials and early commercial activities across many programs.


FREMONT, CA: Cell therapy is used to treat cancer, autoimmune disease, urinary difficulties, and infectious disease, as well as to heal damaged cartilage in joints, spinal cord injuries, strengthen a weakened immune system, and assist individuals with neurological abnormalities. BioCardia, Inc., a developer of cellular and cell-derived medicines to treat cardiovascular and pulmonary illnesses, has leased a new site in Sunnyvale, California, for an indefinite period. This facility is being expanded to accommodate BioCardia's cell and device products and product candidates in the Company's therapeutic pipeline.


"We have always believed that manufacturing during development needs to be kept close to capture new insights and innovate rapidly. Controlling manufacturing at this stage helps accelerate the development of our cell-based medicines, which we also believe is a key differentiator of BioCardia from many other cellular therapeutics companies," comments Peter Altman, BioCardias President and CEO.


 "We expect to soon see all four of the programs we discuss publicly in the clinic helping patients, with our in-house facilities providing the material."


The Company's patented biotherapeutic delivery systems, which the Company also selectively licenses to other biotherapeutic development organizations, are at the heart of three experimental medicines. NK1R+ allogenic bone marrow-derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases are being developed by BioCardia, Inc., based in San Carlos, California, as are CardiAMP cardiovascular-specific mononuclear cell therapy and CardiAMP allogenic cardiovascular-specific mesenchymal stem cell therapies. Products that could benefit millions of people can support these four platforms.


BioCardias' new production facility is planned to produce CardiAMP Cell Therapy Systems, NK1R+ stem cells, and Biotherapeutic Delivery Devices to support various clinical trials and early commercial activities.


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/biocardia-to-support-development-of-potential-cell-therapy-products--nwid-677.html